BGNE – beigene, ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
12/27
06:04 am
bgne
Low
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy [Yahoo! Finance]
12/27
06:00 am
bgne
Low
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
12/24
06:18 am
bgne
Low
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns [Yahoo! Finance]
12/23
06:00 am
bgne
Low
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
12/12
07:30 pm
bgne
Medium
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
11/12/2024
06:00 am
bgne
-1.3%
MISS
8/7/2024
06:00 am
bgne
2.7%
BEAT
5/8/2024
06:00 am
bgne
6.1%
BEAT
2/26/2024
06:00 am
bgne
2.0%
BEAT
12/3
08:59 am
Reiterates
Overweight
Morgan Stanley
Low
0.2%
12/3
08:59 am
Reiterates
Overweight
Morgan Stanley
Low
0.2%
12/3
08:56 am
Assumes
Overweight
Morgan Stanley
Low
0.2%
12/3
08:56 am
Assumes
Overweight
Morgan Stanley
Low
0.2%
10/22
12:54 pm
Maintains
Overweight
Overweight
JP Morgan
Low
0.5%
12/23
06:06 am
bgne
Low
Form 8-K BeiGene, Ltd. For: Dec 23
12/17
05:02 pm
bgne
Low
Form 4 BeiGene, Ltd. For: Dec 14 Filed by: OYLER JOHN
12/12
05:18 pm
bgne
Medium
Form 4 BeiGene, Ltd. For: Dec 10 Filed by: Wang Xiaodong
12/10
09:31 pm
bgne
Low
Form SC 13D/A BeiGene, Ltd. Filed by: BAKER BROS. ADVISORS LP
12/10
09:26 pm
bgne
Low
Form 4 BeiGene, Ltd. For: Dec 09 Filed by: BAKER JULIAN
Show more
Top News Gainers
10/31 Amgen to take 20.5% stake in BeiGene to expand in China [Reuters (UK)] 37.2%
5/9 Q1/2019 3/31/2019 EPS -2.810 ZacksConsensus -3.090 ActVsEst 0.280 - Beat 10.7%
5/14 Beigene Ltd (NASDAQ: BGNE) had its price target raised by analysts at Morgan Stanley from $200.00 to $210.00. They now have an "overweight" rating on the stock. 8.1%
4/13 BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis 6.6%
3/13 Beigene Ltd (NASDAQ: BGNE) was upgraded by analysts at Macquarie from an "underperform" rating to a "neutral" rating. 6.2%
10/16 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $170.00 price target on the stock. 5.5%
12/16 Week In Review: Alphamab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session [Seeking Alpha] 4.5%
11/18 Form 4 BeiGene, Ltd. For: Nov 15 Filed by: Wu Xiaobin 4.0%
9/8 BeiGene to Hold Conference Call and Webcast on September 8, 2019 at 7:00 p.m. ET to Provide Corporate Update 4.0%
9/11 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 4.0%
Top News Decliners
9/26 BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019 -12.8%
4/30 Form 4 BeiGene, Ltd. For: Apr 29 Filed by: Huang Jane -8.3%
9/5 Form 4 BeiGene, Ltd. For: Sep 03 Filed by: Huang Jane -8.0%
6/5 BeiGene to Present at the Goldman Sachs 40th Annual Global Healthcare Conference -7.2%
6/14 BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA) -6.9%
9/9 BeiGene rebounds from bearish report-stoked selloff, up 8% [Seeking Alpha] -6.3%
12/16 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia -6.2%
4/29 BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting -5.8%
3/3 Beigene Ltd (NASDAQ: BGNE) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $200.00 price target on the stock. -5.7%
3/25 BeiGene Announces Supply Update for ABRAXANE® in China -5.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3